Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Richard Daniell Sells 20,003 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 20,003 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $42.80, for a total value of $856,128.40. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $2,386,314. This represents a 26.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Richard Daniell also recently made the following trade(s):

• On Monday, November 9th, Richard Daniell sold 25,000 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $42.91, for a total value of $1,072,750.00.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded up $0.28 during trading hours on Thursday, hitting $43.52. 9,218,408 shares of the company were exchanged, compared to its average volume of 6,859,138. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The company has a market capitalization of $50.72 billion, a PE ratio of 101.22, a PEG ratio of 3.97 and a beta of 0.97. The firm has a fifty day simple moving average of $39.88 and a 200-day simple moving average of $34.96. Teva Pharmaceutical Industries Ltd. has a one year low of $24.01 and a one year high of $44.31.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same period in the previous year, the firm earned $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently bought and sold shares of the business. WCM Investment Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares in the last quarter. Swiss National Bank grew its position in Teva Pharmaceutical Industries by 28.7% during the first quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock valued at $127,344,000 after purchasing an additional 941,700 shares in the last quarter. National Pension Service grew its position in Teva Pharmaceutical Industries by 4.9% during the second quarter. National Pension Service now owns 2,406,013 shares of the company’s stock valued at $81,516,000 after purchasing an additional 112,357 shares in the last quarter. Barometer Capital Management Inc. acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $2,343,000. Finally, Royal Bank of Canada increased its stake in Teva Pharmaceutical Industries by 11.2% in the 1st quarter. Royal Bank of Canada now owns 963,824 shares of the company’s stock valued at $29,030,000 after buying an additional 96,938 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

More Teva Pharmaceutical Industries News

Here’s some of the latest news about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and upgraded Teva to “overweight,” implying about 28% upside from the cited $43.74 share price. Piper Sandler ratings
• Positive Sentiment: At its R&D Day, Teva set a goal of $6 billion to $7 billion in innovative-medicines revenue by 2030, saying revenue from these medicines has more than doubled since its 2023 growth strategy began. The company also highlighted pipeline candidates for Tourette syndrome, celiac disease and intestinal scarring—potential sources of future growth if developed successfully. Teva R&D Day announcement
• Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Zacks Research downgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. TD Cowen lifted their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. HC Wainwright initiated coverage on shares of Teva Pharmaceutical Industries in a report on Monday, November 2nd. They set a “buy” rating and a $52.00 price target on the stock. Finally, Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an “overweight” rating in a research report on Thursday. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.15.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.